临床试验中的结核病疫苗。
Tuberculosis vaccines in clinical trials.
机构信息
The Jenner Institute, Old Road Campus Research Building, Oxford University, Oxford, OX3 7DQ, UK.
出版信息
Expert Rev Vaccines. 2011 May;10(5):645-58. doi: 10.1586/erv.11.28.
Abstract
Effective prophylactic and/or therapeutic vaccination is a key strategy for controlling the global TB epidemic. The partial effectiveness of the existing TB vaccine, bacille Calmette-Guérin (BCG), suggests effective vaccination is possible and highlights the need for an improved vaccination strategy. Clinical trials are evaluating both modifications to the existing BCG immunization methods and also novel TB vaccines, designed to replace or boost BCG. Candidate vaccines in clinical development include live mycobacterial vaccines designed to replace BCG, subunit vaccines designed to boost BCG and therapeutic vaccines designed as an adjunct to chemotherapy. There is a great need for validated animal models, identification of immunological biomarkers of protection and field sites with the capacity for large-scale efficacy testing in order to develop and license a novel TB vaccine or regimen.
摘要
有效的预防性和/或治疗性疫苗接种是控制全球结核病流行的关键策略。现有的结核病疫苗卡介苗（BCG）的部分有效性表明有效的疫苗接种是可能的，并突出了需要改进的疫苗接种策略。临床试验正在评估对现有卡介苗免疫方法的修改，以及旨在替代或增强卡介苗的新型结核病疫苗。正在临床开发中的候选疫苗包括旨在替代卡介苗的活分枝杆菌疫苗、旨在增强卡介苗的亚单位疫苗以及作为化疗辅助剂的治疗性疫苗。为了开发和许可新型结核病疫苗或方案，非常需要经过验证的动物模型、鉴定保护性免疫生物标志物以及具有大规模疗效测试能力的现场站点。
相似文献
1
Tuberculosis vaccines in clinical trials.临床试验中的结核病疫苗。
Expert Rev Vaccines. 2011 May;10(5):645-58. doi: 10.1586/erv.11.28.
2
Tuberculosis vaccines: progress and challenges.结核病疫苗：进展与挑战。
Trends Pharmacol Sci. 2011 Oct;32(10):601-6. doi: 10.1016/j.tips.2011.06.003. Epub 2011 Jul 29.
3
Tuberculosis vaccines: beyond bacille Calmette-Guerin.结核病疫苗：超越卡介苗。
Philos Trans R Soc Lond B Biol Sci. 2011 Oct 12;366(1579):2782-9. doi: 10.1098/rstb.2011.0097.
4
Clinical Testing of Tuberculosis Vaccine Candidates.结核病候选疫苗的临床检测。
Microbiol Spectr. 2016 Oct;4(5). doi: 10.1128/microbiolspec.TBTB2-0015-2016.
5
Heterologous boost vaccines for bacillus Calmette-Guérin prime immunization against tuberculosis.用于卡介苗初免的结核异源加强疫苗。
Expert Rev Vaccines. 2007 Aug;6(4):539-46. doi: 10.1586/14760584.6.4.539.
6
Antituberculous vaccine development: a perspective for the endemic world.抗结核疫苗的研发：面向流行地区的视角。
Expert Rev Vaccines. 2009 Nov;8(11):1547-53. doi: 10.1586/erv.09.111.
7
Vaccine development for tuberculosis: current progress.结核病疫苗的研发：当前进展。
Drugs. 2013 Jul;73(10):1015-24. doi: 10.1007/s40265-013-0081-8.
8
Tuberculosis vaccine: time to look into future.结核病疫苗：展望未来之时。
Hum Vaccin Immunother. 2014;10(2):420-2. doi: 10.4161/hv.27108. Epub 2013 Nov 14.
9
Novel tuberculosis vaccines on the horizon.新型结核疫苗呼之欲出。
Curr Opin Immunol. 2010 Jun;22(3):374-84. doi: 10.1016/j.coi.2010.04.006. Epub 2010 May 12.
10
Tuberculosis vaccine: A journey from BCG to present.结核疫苗：从卡介苗到现在的历程。
Life Sci. 2020 Jul 1;252:117594. doi: 10.1016/j.lfs.2020.117594. Epub 2020 Apr 16.
引用本文的文献
1
screening and identification of CTL and HTL epitopes in the secreted virulence factors of Mycobacterium tuberculosis.结核分枝杆菌分泌毒力因子中细胞毒性T淋巴细胞和辅助性T淋巴细胞表位的筛选与鉴定
BioTechnologia (Pozn). 2025 Mar 31;106(1):63-76. doi: 10.5114/bta/201461. eCollection 2025.
2
Trends in Viral Vector-Based Vaccines for Tuberculosis: A Patent Review (2010-2023).基于病毒载体的结核病疫苗研究趋势：专利综述（2010 - 2023年）
Vaccines (Basel). 2024 Aug 2;12(8):876. doi: 10.3390/vaccines12080876.
3
The whole genome sequence of Polish vaccine strain BCG Moreau.波兰疫苗株卡介苗 Moreau 的全基因组序列。
Microbiol Spectr. 2024 Jul 2;12(7):e0425923. doi: 10.1128/spectrum.04259-23. Epub 2024 May 17.
4
Efficacy of light chain 3-fused protein multi epitope in protection of mice challenged with .轻链3融合蛋白多表位在保护受……攻击的小鼠方面的功效 。
（注：原文中“challenged with.”后面内容缺失）
Vet Res Forum. 2023;14(12):659-664. doi: 10.30466/vrf.2023.1975747.3702. Epub 2023 Dec 15.
5
Past, Present and Future of Bacillus Calmette-Guérin Vaccine Use in China.卡介苗在中国应用的过去、现在与未来
Vaccines (Basel). 2022 Jul 20;10(7):1157. doi: 10.3390/vaccines10071157.
6
Controlled Human Infection Models To Accelerate Vaccine Development.控制人体感染模型以加速疫苗开发。
Clin Microbiol Rev. 2022 Sep 21;35(3):e0000821. doi: 10.1128/cmr.00008-21. Epub 2022 Jul 6.
7
An Update on Tuberculosis Vaccines.结核病疫苗的最新研究进展。
Methods Mol Biol. 2022;2410:387-409. doi: 10.1007/978-1-0716-1884-4_20.
8
Hidden in plain sight: The effects of BCG vaccination in the COVID-19 pandemic.隐匿于众目睽睽之下：卡介苗接种在新冠疫情大流行中的作用。
J Med Virol. 2021 Apr;93(4):1950-1966. doi: 10.1002/jmv.26707. Epub 2020 Dec 17.
9
Xyloglucan based mucosal nanovaccine for immunological protection against brucellosis developed by supercritical fluid technology.基于木葡聚糖的黏膜纳米疫苗，通过超临界流体技术研发，用于布鲁氏菌病的免疫保护。
Int J Pharm X. 2020 Jul 30;2:100053. doi: 10.1016/j.ijpx.2020.100053. eCollection 2020 Dec.
10
T Cell Responses to Mycobacterial Glycolipids: On the Spectrum of "Innateness".T 细胞对分枝杆菌糖脂的反应：在“先天”的光谱上。
Front Immunol. 2020 Feb 11;11:170. doi: 10.3389/fimmu.2020.00170. eCollection 2020.
本文引用的文献
1
Perspectives on clinical and preclinical testing of new tuberculosis vaccines.对新结核疫苗的临床前和临床测试的看法。
Clin Microbiol Rev. 2010 Oct;23(4):781-94. doi: 10.1128/CMR.00005-10.
2
Delaying bacillus Calmette-Guérin vaccination from birth to 4 1/2 months of age reduces postvaccination Th1 and IL-17 responses but leads to comparable mycobacterial responses at 9 months of age.将卡介苗接种延迟至出生后 4 个半月，可降低接种后的 Th1 和 IL-17 反应，但在 9 个月时可产生类似的分枝杆菌反应。
J Immunol. 2010 Aug 15;185(4):2620-8. doi: 10.4049/jimmunol.1000552. Epub 2010 Jul 19.
3
Specific T cell frequency and cytokine expression profile do not correlate with protection against tuberculosis after bacillus Calmette-Guérin vaccination of newborns.特异性 T 细胞频率和细胞因子表达谱与新生儿接种卡介苗后预防结核病的效果无关。
Am J Respir Crit Care Med. 2010 Oct 15;182(8):1073-9. doi: 10.1164/rccm.201003-0334OC. Epub 2010 Jun 17.
4
The population dynamics and control of tuberculosis.结核病的种群动态与控制。
Science. 2010 May 14;328(5980):856-61. doi: 10.1126/science.1185449.
5
The immunology of tuberculosis: from bench to bedside.结核病的免疫学：从基础到临床。
Respirology. 2010 Apr;15(3):433-50. doi: 10.1111/j.1440-1843.2010.01739.x.
6
Effect of revaccination with BCG in early childhood on mortality: randomised trial in Guinea-Bissau.BCG 疫苗复种对婴幼儿死亡率的影响：几内亚比绍的随机试验
BMJ. 2010 Mar 15;340:c671. doi: 10.1136/bmj.c671.
7
Ag85B-ESAT-6 adjuvanted with IC31 promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naïve human volunteers.Ag85B-ESAT-6 佐剂与 IC31 联合促进了初免人类志愿者中强烈和持久的结核分枝杆菌特异性 T 细胞应答。
Vaccine. 2010 Apr 30;28(20):3571-81. doi: 10.1016/j.vaccine.2010.02.094. Epub 2010 Mar 11.
8
Vitamin A supplementation and BCG vaccination at birth in low birthweight neonates: two by two factorial randomised controlled trial.维生素 A 补充剂和卡介苗接种在低出生体重儿出生时：两因素两水平析因随机对照试验。
BMJ. 2010 Mar 9;340:c1101. doi: 10.1136/bmj.c1101.
9
Stopping tuberculosis in the 21st century: goals and strategies.在 21 世纪终止结核病：目标与策略。
Respirology. 2010 Jan;15(1):32-43. doi: 10.1111/j.1440-1843.2009.01673.x.
10
The novel tuberculosis vaccine, AERAS-402, induces robust and polyfunctional CD4+ and CD8+ T cells in adults.新型结核疫苗 AERAS-402 可诱导成人产生强大且多功能的 CD4+和 CD8+T 细胞。
Am J Respir Crit Care Med. 2010 Jun 15;181(12):1407-17. doi: 10.1164/rccm.200910-1484OC. Epub 2010 Feb 18.
Zotero 插件